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Background: Acute lymphoblastic leukemia (ALL) is a heterogeneous group of malignant disorders derived from B- or
T-cell lymphoid progenitor cells. ALL often is refractory to or relapses after treatment; thus, novel targeted therapy for
ALL is urgently needed. In the present study, we initially found that the level of SIRT1, a class III histone deacetylase, was
higher in primary ALL cells from patients than in peripheral blood mononuclear cells from healthy individuals. But it is
not clear whether inhibition of SIRT1 by its selective small molecule inhibitor Tenovin-6 is effective against ALL cells.
Methods: We tested the effect of Tenovin-6 on ALL cell lines (REH and NALM-6) and primary cells from 41 children
with ALL and 2 adult patients with ALL. The effects of Tenovin-6 on cell viability were determined by MTS assay;
colony-forming assays were determined by soft agar in ALL cell lines and methylcellulose medium in normal
bone marrow cells and primary ALL blast cells; cell apoptosis and cell cycling were examined by flow cytometry;
the signaling pathway was determined by Western blotting; ALL stem/progenitor cells were seperated by using
MACS MicroBead kit.
Results: The results showed that Tenovin-6 treatment activated p53, potently inhibited the growth of pre-B ALL
cells and primary ALL cells, and sensitized ALL cells to frontline chemotherapeutic agents etoposide and cytarabine.
Tenovin-6 induced apoptosis in REH and NALM-6 cells and primary ALL cells and diminished expression of Mcl-1 and
X-linked inhibitor of apoptosis protein (XIAP) in such cells. Furthermore, inhibition of SIRT1 by Tenovin-6 inhibited the
Wnt/β-catenin signaling pathway and eliminated ALL stem/progenitor (CD133 + CD19-) cells.
Conclusion: Our results indicate that Tenovin-6 may be a promising targeted therapy for ALL and clinical trials
are warranted to investigate its efficacy in ALL patients.
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Acute lymphoblastic leukemia (ALL) is a heterogeneous
group of malignant disorders derived from B- or T-cell
lymphoid progenitor cells. ALL is ranked as the fifth most
common childhood cancer and accounts for a large propor-
tion of cancer-associated deaths in children every year [1].
Over the past 50 years, advances in chemotherapy regimens* Correspondence: panjx2@mail.sysu.edu.cn
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unless otherwise stated.have increased the cure rate for children with newly diag-
nosed ALL in the developed world to approximately 85%
[1]. However, the remaining approximately 15% of children
with ALL are not expected to survive because of relapse [2].
The problems of relapse, morbidity, and mortality are even
more pronounced in adult patients with ALL. Novel treat-
ments are desperately needed in order to improve survival
in patients with ALL that is refractory to treatment or
relapses after an initial response.
ALL has been shown to be associated with genetic
and epigenetic alterations [3], and progress in elucidat-
ing the pathogenesis of ALL has revealed a large num-
ber of potential targets for anticancer therapy. For example,is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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30% of cases of ALL in adults has been successfully trans-
lated into treatment with small molecule tyrosine kinase
inhibitors (e.g., imatinib and bosutinib) [4]. The ETV6-
RUNX1 fusion gene is found in approximately 25% of
cases of ALL in children [5]. Chatterton et al. reported
that 325 genes were hypermethylated and downregulated
and 45 genes were hypomethylated and upregulated in
pediatric B-cell ALL [6]. Epigenetic alteration indicates
that targeted therapy against ALL is promising. Excitingly,
vorinostat, a pan-histone deacetylase inhibitor, and more
recently romidepsin, a bicyclic pan-histone deacetylase
inhibitor, have been approved by the US Food and
Drug Administration for treatment of relapsed or refrac-
tory cutaneous T-cell lymphoma [7].
Reversible protein acetylation is an important posttrans-
lational modification that regulates the function of his-
tones and many other proteins [8]. Histone acetylation is
mediated by histone acetyl transferases (e.g., p300, CBP,
and p/CAF in mammalian cells), while acetyl groups are
removed by histone deacetylases [9]. Recently, the histone
deacetylase sirtuin 1 (SIRT1) has been shown to be im-
portant in leukemia. Sirtuin 1 (SIRT1) is a stress-response
and chromatin-silencing factor belonging to the class III
histone deacetylases family, which is involved in various
nuclear events such as transcription, DNA replication,
and DNA repair [10]. SIRT1 has been shown to inhibit
the maturation of preadipocytes [11] and promote resist-
ance to conventional chemotherapeutic agents [12,13].
Additionally, mammalian SIRT1 is a key regulator of can-
cer cell survival in the face of cellular stresses. SIRT1 and
other sirtuins were found to regulate cell survival during
stress through deacetylation of key cell cycle and apoptosis
regulatory proteins, including p53 [14,15], Ku70 [16], and
forkhead transcription factors [10]. Of importance, SIRT1
is highly overexpressed in several types of tumors [17].
Recently, SIRT1 has been demonstrated to promote
Bcr-Abl-driven leukemogenesis and the survival of chronic
myelogenous leukemia stem cells [18,19].
In the present study, we initially discovered that SIRT1
level was higher in primary ALL cells than in control
cells. We then hypothesized that inhibition of SIRT1 by
its specific small molecule inhibitor Tenovin-6 induces
apoptosis in ALL cells by releasing the expression of tumor
suppressor genes such as p53. We tested this hypothesis in
ALL cell lines (REH and NALM-6) and in primary cells
from 41 children with ALL and 2 adult patients with ALL.
Our findings suggest that Tenovin-6 may be a promising
agent for ALL therapy.
Methods
Reagents
Tenovin-6 was purchased from Cayman Chemical (Ann
Arbor, MI). Antibodies against SIRT1 (H-300), p53(DO-7), cyclin D1 (C-20), Mcl-1 (S-19), and proliferating
cell nuclear antigen (PCNA) were from Santa Cruz
Biotechnology (Santa Cruz, CA). Antibodies against
PARP (clone 4C10-5), caspase-3, XIAP, and anti-CD19
conjugated with phycoerythrin were from BD Biosci-
ences (San Jose, CA). Antibodies against K382-acetyl-
p53 and c-Myc were from Cell Signaling Technology
(Beverly, MA). Anti-SIRT2 was purchased from Atlas
Antibodies. The CD133 MicroBead Kit including anti-
CD133 conjugated with APC was from Miltenyi Biotec,
Inc. (Shanghai, China). Anti-mouse immunoglobulin G
and anti-rabbit immunoglobulin G horseradish peroxidase-
conjugated secondary antibodies were from Pierce
Biotechnology (Rockford, IL).
Cell culture
REH and NALM-6 cells from American Type Culture
Collection (Rockville, MD) were cultured in RPMI 1640
(Invitrogen, Shanghai) supplemented with fetal calf serum
(FCS; Kibbutz Beit, Haemek, Israel) and 100 units/mL
penicillin and streptomycin at 37°C in a humidified
atmosphere of 95% air and 5% CO2.
Primary cells from patients with ALL
Peripheral blood or bone marrow samples from 43 patients
with ALL (Children with ALL, 41 cases; Adult patients
with ALL, 2 cases), acute myelogenous leukemia (AML;
4 cases), Lymphoma (1 case), and 5 healthy adult donors
were obtained from the Sun Yat-sen Memorial Hospital of
Sun Yat-sen University and Guangdong Provincial People’s
Hospital. This study was approved by the Sun Yat-sen
University Ethics Committee according to institutional
guidelines and the Declaration of Helsinki principles, and
written informed consent to participate in this research
and written informed consent to publish the resultant re-
sults were obtained from all the patients involved or their
legal guardians for children under the age of 16. The clin-
ical information for the 48 patients is in Table 1.
Mononuclear cells were isolated by Histopaque gradient
centrifugation (density 1.077; Sigma-Aldrich, Shanghai)
[20-22]. Contaminating red cells were removed by incuba-
tion in 0.8% ammonium chloride solution for 10 min.
After a washing, cells were suspended in RPMI 1640
medium supplemented with 10% FCS. All drug treatments
started after the cells were precultured in fresh medium
for 24 hours.
For separation of stem/progenitor cells of ALL, the
mononuclear cells were mixed with MicroBeads conju-
gated to monoclonal anti-human CD133 antibodies
(isotype: mouse IgG1, clone AC133) and loaded onto
a MACS column with separator according to the instruc-
tions from Miltenyi Biotec Inc [20]. After removing from
the magnetic field, the magnetically retained CD133+ cells
were eluted as the positively selected cell fraction.
Table 1 Clinical characteristic of patients with leukemia
Patient Age, years/sex WBC count (×109) Diagnosis Mutations Initial or relapsed
disease
IC50 for Tenovin-6, μM
1 11/M 216.45 ALL-L2, B BCR/ABL (+, 72%) Initial 5.44
2 4/M 1.09 ALL-L2, B Neg Initial 14.65
3 3/F 4.27 ALL-L2, B Neg Initial 8.05
4 10.6/M 17.66 ALL-L2, B Neg Initial 4.7
5 0.6/M 23.16 ALL-L2, B Neg Initial 2.72
6 10/F 531 ALL-L2, T Neg Initial 7.49
7 2.3/F 14.97 ALL-L2, B MLL (+, 82%) Initial 7.15
8 10/M 22.98 ALL-L2, T Neg Initial 10.49
9 10.6/M 17.66 ALL-L2, B Neg Initial 2.03
10 2.4/F 24 ALL-L2, B Neg Relapsed 5.9
11 10/M 43.8 ALL-T Neg Relapsed 4.5
12 1.9/M 44.2 ALL-L2, B Neg Initial 3.03
13 3.5/F 5.2 AML-M0 Neg Initial 8.15
14 1.6/F 5.1 AML-M7 Neg Initial 3.08
15 3/M 4.27 ALL-L2, B Neg Initial 2.88
16 2/M 58.9 ALL-L1, B unknown Initial 4.03
17 13/M 5.66 ALL-L2, B Neg Relapsed 6.98
18 9.5/M 10.59 ALL-L2, B Neg Initial 7.21
19 0.7/M 43 ALL-L2, B Neg Initial 13.82
20 7/M 6.55 ALL-L2, B Neg Relapsed 17
21 0.2/M 54.83 ALL-L2, B MLL (+, 86%) Initial 4.83
22 0.5/M 208.85 ALL-L2, B Neg Initial 3.8
23 0.8/F 137.41 ALL-L2, B MLL (+, 96%) Initial 7.24
24 11/M 24.06 ALL-L2, B Neg Initial 3.91
25 11/M 56.8 ALL, mature B Neg Initial 4.26
26 2/F 281.31 ALL-L1, T Neg Initial 4.13
27 10/F 34.7 AML-M3b PML-RARa (+, 35%) Initial 7.83
28 3/F 8.07 ALL-L2, B TEL/AML1 (+, 85%) Initial 3.58
29 14.2/M 104 ALL-L2, B BCR/ABL (+, 82%) Initial 3.75
30 12/M 384 ALL-L2, B Neg Initial 8.16
31 4/M 2.01 ALL-L2, B TEL/AML (+, 75%) Initial 6.15
32 12/M 189 ALL-L2, T Neg Initial 7.07
33 1.5/F 4.7 ALL-L2, B Neg Initial 4.74
34 2/F 26.7 ALL Neg Initial 5.32
35 9/F 3.8 ALL-L2, B Neg Initial 12.48
36 4.2/M 17.4 ALL-L2, B Neg Initial 6.2
37 6/F 52.53 ALL-L2, B TEL/AML (+) Initial 3.35
38 8/M 8.95 ALL-T Neg Initial 4.31
39 8/M 34.3 ALL-L2, B Neg Initial 4.03
40 5/M 26.46 ALL-L2, B Neg Initial 12.56
41 9/M 3.29 ALL-L2, B Neg Initial 10.2
42 1/M 21.6 AML Neg Initial 14.75
43 12/M 82.79 ALL-L1, T Neg Initial 6.65
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Table 1 Clinical characteristic of patients with leukemia (Continued)
44 4/M 6.62 Lymphoma Unknown Initial 4.81
45 0.8/F 137.41 ALL-L2 MLL (+, 96%) Initial 13.22
46 11/M 24.06 ALL-L2 Neg Initial 16.38
47 55/F 62.75 ALL Neg Initial ND
48 28/F 2.65 ALL Neg Initial ND
AML, acute myelogenous leukemia; WBC, white blood cell; Neg, negative; ND, not detected.
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staining of CD133-APC.
Cell viability assay
Cell viability was evaluated by MTS assay (CellTiter 96
AQueous One Solution reagent, Promega, Shanghai) as
described previously [20-22]. The IC50 was determined
by curve fitting of the dose–response curve.
Colony-forming assays
Soft agar clonogenic assay in ALL cell lines
ALL cell lines were treated with Tenovin-6 or diluent
(DMSO, control) for 24 hours, washed with PBS, and
seeded in Iscove's medium containing 0.3% agar and
20% FCS in the absence of drug treatment [20-22].
Colony-forming assay in normal bone marrow cells and
primary ALL blast cells
The colony-forming capacity of normal bone marrow
cells and primary ALL blast cells was analyzed by use of
methylcellulose medium (Methocult H4434, Stem Cell
Technologies) according to the manufacturer's instruc-
tions. Tenovin-6 was added to the initial cultures at a
concentration of 1 μM to 10 μM. After 14 days of cul-
ture, the number of colony-forming units was evalu-
ated under an inverted microscope according to standard
criteria [20-22].Figure 1 The levels of SIRT1 and SIRT2 are increased in primary malig
SIRT1 in whole cell lysates from 7 patients with ALL (A) and REH and NALM
SIRT2 in whole cell lysates from 7 patients with ALL (C) and REH and NALMReverse transcription and quantitative real-time PCR
Total RNA from cultured cells was extracted using
Trizol reagent (Invitrogen, Shanghai). Two micrograms
of RNA was processed directly to cDNA by reverse
transcription with SuperScript III following the manu-
facturer’s instructions (Invitrogen, Shanghai). PCR primers
for each gene were designed using real-time PCR primer
design; sequences used in this study were as follows: p53,
forward 5’-GTGGAAGGAAATTTGCGTGT-3’, reverse
5’-TGGTGGTACAGTCAGAGCCA-3’; p21, forward 5’-G
ACTCTCAGGGTCGAAAACGG-3’, reverse 5’-GCGGAT
TAGGGCTTCCTCTT-3’; Noxa, forward 5’-GCAAGAAC
GCTCAACCGAG-3’, reverse 5’-TTGAAGGAGTCCCCT
CATGC-3’; Puma,forward 5’-ACCTCAACGCACAGTAC
GAG-3’, reverse 5’-CGGGTGCAGGCACCTAATTG’; Bax,
forward 5’-GAACCATCATGGGCTGGACA’, reverse 5’-G
CGTCCCAAAGTAGGAGAGG’; c-myc, forward 5’-CAG
CGACTCTGAGGAGGAAC-3’, reverse 5’-TCGGTTGTT
GCTGATCTGTC-3’; cyclin-D1, forward 5’-GCTGTGCA
TCTACACCGACA-3’, reverse 5’-CCACTTGAGCTTGTT
CACCA-3’; LEF1, forward 5’-CGAATGTCGTTGCTGAG
TGT-3’, reverse 5’-GCTGTCTTTCTTTCCGTGCT-3’; 18 s,
forward 5’-AAACGGCTACCACATCCAAG-3’, reverse
5’-CCTCCAATGGATCCTCGTTA-3’. We used SYBR
Premix Ex Taq (Perfect Real-time; Takara Bio) for qRT-
PCR with Applied Biosystems 7500 Real-time PCR System
(Applied Biosystems) according to the manufacturer’snant cells from patients with ALL. Western blotting analysis of
-6 ALL cells and 2 healthy individuals (B). Western blotting analysis of
-6 ALL cells and 2 healthy individuals (D).
Figure 2 Tenovin-6 induces activation of p53 in ALL cells. A, Molecular structure of SIRT1/2 inhibitor Tenovin-6. B, REH and NALM-6 ALL cells
were treated with increasing concentrations of Tenovin-6 for 24 and 36 hours. Acetylated p53, total p53 protein, and SIRT1 were detected by
Western blotting analysis with the indicated antibodies. C, REH and NALM-6 cells were exposed to 1 μM Tenovin-6 for the indicated times, and
acetylated p53, total p53 protein, and SIRT1 were detected by Western blotting. D, REH cells were treated with 1 μM Tenovin-6 for the indicated
times, and mRNA levels of p53 and its targets-genes p21, Puma, Noxa and Bax were examined by real-time PCR. 18 s rRNA was used as an
internal reference.
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Figure 3 Tenovin-6 inhibits the growth of ALL cells. A, REH and NALM-6 ALL cells were exposed to Tenovin-6 for 72 hours. Cell viability (percentage
relative to control) was determined by MTS assay. Tenovin-6 dose–response curves are shown. B & C, Mononuclear cells from peripheral blood of 46 children
with primary (“Initial”) or relapsed ALL and from bone marrow of 5 healthy individuals (normal bone marrow; NBM) were exposed to increasing
concentrations of Tenovin-6 and then subjected to MTS assay. Representative dose–response curves (B) and IC50 values of Tenovin-6 for
all patients and healthy individuals (C) are shown. D, Tenovin-6 inhibited the clonogenicity of ALL cells. REH and NALM-6 cells were
seeded in soft agar with the indicated concentrations of Tenovin-6 for 14 days, and then colony-forming units were counted. * P < 0.05, ** P <0.01,
one-way ANOVA, post hoc comparisons, Tukey’s test; error bars represent 95% CIs. E, Colony-forming capacity of primary ALL bone marrow cells from 4
children with ALL and 3 normal bone marrow cells were evaluated by using methylcellulose medium with the indicated concentration of Tenovin-6. A
representative curve is shown. F, Cell cycle distributions in REH and NALM-6 cells after exposure to increasing concentrations of Tenovin-6. * P < 0.05
compared with control.
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on agarose gel. Expression levels of 18S rRNA were used
as an endogenous reference.
Western blotting analysis
Whole cell lysates prepared in RIPA (radioimmunopreci-
pitation) assay buffer (1 × PBS, 1% NP-40, 0.5% sodium
deoxycholate, 0.1% SDS, 0.1 mg/ml phenylmethanesulfo-
nyl fluoride, 20 mM sodium fluoride, 0.2 mM sodium
orthovanadate, and Complete Protease Inhibitor Mix, one
tablet per 50 ml) [20-22]. Cytoplasmic and nuclear frac-
tions were prepared as described previously [20-22].
Protein samples were separated on SDS-PAGE gel and
transferred to nitrocellulose membranes, which were
then incubated with the primary antibodies. After in-
cubation with appropriate secondary antibodies, the
immunoblots were developed using SuperSignal Western
blotting kits (Pierce Biotechnology) and exposed to X-ray
film according to the manufacturer’s protocol. Western
blots were stripped between hybridizations with stripping
buffer [10 mM Tris–HCl (pH 2.3) and 150 mM NaCl].
Flow cytometry analysis of cell cycle
After drug treatment, cells were collected and fixed
overnight in 66% cold ethanol at −20°C. The cells were
then washed twice in cold PBS and labeled with propi-
dium iodide for 1 hour in the dark. Cell cycle distribu-
tion was determined by use of a FACSCalibur flow
cytometer with CellQuest software [20-22].
Measurement of apoptosis
Apoptosis was evaluated with an AnnexinV-fluoroisothiocyanate
apoptosis detection kit according to the instructions of the
manufacturer (Sigma-Aldrich, Shanghai) and analyzed
with use of a FACSCalibur flow cytometer and CellQuest
software as previously described [20-22].
Electrophoretic mobility shift assay
The WT-TCF probe was prepared by annealing 5’-TG
CCGGGCTTTGATCTTTG-3’ and 5’-AGCAAAGATCA
AAGCCCGG-3’ deoxyoligonucleotides [23]. Double-
stranded probes were end-labeled using biotin. EMSA was
performed with use of the Light Shift ChemiluminescentEMSA kit (Pierce Biotechnology) according to the manu-
facturer's instructions [20].
Statistical analysis
Data from all the experiments are expressed as mean ±
95% CI unless otherwise stated. GraphPad Prism 5.0
software (GraphPad Software, San Diego, CA) was used
for statistical analysis. Comparisons among multiple
groups involved one-way ANOVA with post-hoc inter-
group comparison with the Tukey test. P < 0.05 was con-
sidered statistically significant.
Results
SIRT1/2 are increased in primary leukemia cells from
patients with ALL and in ALL cell lines
We first examined whether SIRT1 was increased in pri-
mary leukemia cells from patients with ALL. By using
Western blotting, we examined the levels of SIRT1 in
whole cell lysates of mononuclear cells from peripheral
blood or bone marrow from 7 patients with ALL and 2
healthy individuals. The results revealed that the level of
SIRT1 protein was higher in the whole cell lysates from
the patients with ALL than in the whole cell lysates from
the healthy individuals (Figure 1A). SIRT1 was also highly
expressed in REH and NALM-6 ALL cells (Figure 1B). We
also determined the levels of SIRT2 in ALL cells with
Western blotting analysis. The expression of SIRT2
was much higher in the primary leukemia cells from
ALL patients and in ALL cell lines than normal cells
(Figure 1C and D).
Tenovin-6-mediated inhibition of SIRT1/2 leads to
hyperacetylation of p53 in ALL cells
Tenovin-6 (molecular structure, Figure 2A) has been
shown to inhibit the deacetylation activity of SIRT1 and
SIRT2 [24]. We next examined the effect of Tenovin-6-
mediated SIRT1/2 inhibition on the acetylation status of
p53, an important substrate of SIRT1. Toward this end,
REH and NALM-6 cells were exposed to increasing con-
centrations of Tenovin-6 for 24 and 36 hours. Western
blotting of whole cell lysates revealed the anticipated increase
in total and hyperacetylated p53 protein (Figure 2B). A time-
course study showed that Tenovin-6 at a concentration as
Figure 4 (See legend on next page.)
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Figure 4 Tenovin-6 induces apoptosis in ALL cells. A, REH and NALM-6 cells were treated with increasing concentrations of Tenovin-6 for 24
or 48 hours. Apoptosis was determined by flow cytometry after Annexin V-FITC/propidium iodide staining. Representative histograms (left) and
results for 3 independent experiments (right) are shown. B, Dead cells (including apoptotic and necrotic cells) in primary cells from children
with ALL were examined by flow cytometry after treatment with Tenovin-6 for 48 hours. Histograms from 2 representative patients (left) and
statistical analysis in 3 patients (right) are shown. * P < 0.05, ** P <0.01, one-way ANOVA, post hoc comparisons, Tukey’s test; error bars represent
95% CIs. C, REH and NALM-6 cells were treated with the indicated concentrations of Tenovin-6 for 24 or 48 hours. Time- and dose-dependent cleavage
of PARP and levels of pro-caspase 3, Mcl-1, and XIAP were detected by Western blotting.
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2 hours, and that this increase was followed by a time-
dependent increase in the acetylation level of p53 in both
REH and NALM-6 cells (Figure 2C).
To evaluate whether Tenovin-6 increased p53 activa-
tion, we examined the transcription of known p53 target
genes p21, Puma, Noxa and Bax. In accordance with the
increased acetylation level of p53 after Tenovin-6 treat-
ment, quantitative reverse transcriptase-polymerase chain
reaction (qRT-PCR) analysis showed that Tenovin-6 ap-
preciably promoted the transcription of p21, Puma, and
Bax, but Noxa without changing the mRNA level of p53
(Figure 2D).
Tenovin-6 inhibits the growth of ALL cells
The effect of Tenovin-6 on the viability of ALL cells was
first examined by MTS assay. Tenovin-6 dose-dependently
inhibited the growth of ALL cells; the drug concentrations
resulting in 50% inhibition of cell growth (IC50 values) were
0.36 μM and 2.5 μM in REH and NALM-6 cells, respect-
ively (Figure 3A). Because of these findings, we were curi-
ous to see whether Tenovin-6 also inhibited the growth of
primary cells from patients with ALL. Peripheral blood
mononuclear cells isolated from 43 patients with ALL
(Table 1) and normal bone marrow cells from 5 healthy in-
dividuals were exposed to escalating concentrations of
Tenovin-6 for 72 hours and then subjected to MTS assay
for measurement of cell viability. The results showed that
Tenovin-6 inhibited the growth of primary ALL cells in a
dose-dependent manner; median IC50 values were 6.2 μM
(range, approximately 2.03-17 μM) for ALL cells (Figure 3B
& C and Table 1) and approximately 10 μM in normal
bone marrow cells (Figure 3B & C). Of note, 4 of the 43
patients with ALL whose cells were treated with Tenovin-6
had relapsed ALL.
We next measured the effect of Tenovin-6 on the
anchorage-independent growth of ALL cells REH and
NALM-6 in soft agar culture. Tenovin-6 dose-dependently
inhibited the number of surviving clonogenic ALL cells,
with IC50 values of approximately 1.0 μM to 2.0 μM
(Figure 3D).
Because of the efficacy of Tenovin-6 in primary cells
from patients with relapsed ALL, we examined the effect
of Tenovin-6 on functionally defined ALL stem/progenitor
cells by methylcellulose colony assay. The colony-formingability of primary ALL cells was strikingly inhibited by
Tenovin-6 in a dose-dependent manner, with a median
IC50 value of 2.59 μM (n = 4; Figure 3E, left). In contrast,
Tenovin-6 inhibited the colony-forming ability of normal
bone marrow cells with a median IC50 value of 7.53 μM
(n = 3, Figure 3E, right).
We also assessed whether Tenovin-6 disturbed the cell
cycle distribution of ALL cells. As shown in Figure 3F,
exposure of ALL cells to increasing concentrations of
Tenovin-6 for 24 hours dramatically arrested the cells in
G1 phase.
Tenovin-6 induces apoptosis in ALL cell lines as well as
primary ALL cells
The impact of Tenovin-6 on apoptosis in ALL cells was
detected by flow cytometry after Annexin V-fluorescein
isothiocyanate (FITC)/propidium iodide staining. Expos-
ure of REH and NALM-6 cells to increasing concentra-
tions (range, approximately 1 to 10 μM) of Tenovin-6
resulted in massive apoptotic cell death (Figure 4A, left).
Statistical analysis of cell death (including apoptotic
and necrotic cells) induced by Tenovin-6 in REH and
NALM-6 cells is presented in Figure 4A (right). Increased
apoptosis was also detected in Tenovin-6-treated primary
ALL cells from patients compared with untreated control
cells (Figure 4B).
By Western blotting, we discovered that Tenovin-6
induced a dose- and time-dependent specific cleavage
of poly(ADP-ribose) polymerase (PARP), a hallmark of
apoptosis, and a decrease in pro-caspase-3, the precur-
sor form of caspase-3, in REH and NALM-6 ALL cells,
indicating onset of apoptosis (Figure 4C). Western blot-
ting also revealed no change in the expression of Bcl-2 but
a substantial decrease in XIAP and Mcl-1 with Tenovin-6
treatment (Figure 4C).
Tenovin-6 sensitizes ALL cells to conventional
chemotherapeutic agents
Because Tenovin-6 increased hyperacetylation of p53
(Figure 2B), we evaluated whether Tenovin-6 treatment
could sensitize ALL cells to the conventional chemothera-
peutic agents etoposide and cytarabine. REH and NALM-6
cells were incubated in a serially diluted mixture (at a fixed
ratio) of Tenovin-6 and etoposide or cytarabine for
72 hours and then subjected to MTS assay for measurement
Figure 5 (See legend on next page.)
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Figure 5 Tenovin-6 sensitizes ALL cells to conventional chemotherapeutic agents. A, Synergistic effect of the combination of Tenovin-6
and etoposide or cytarabine in ALL cells was assessed by MTS assay after incubation of ALL cells with a serial diluted mixture (at a fixed ratio)
of the 2 drugs for 72 hours. CI is plotted against the fraction affected. A reference line is drawn at CI = 1. CI values of <1 indicated synergism
between the 2 drugs. B, REH and NALM-6 cells were treated with the indicated concentrations of Tenovin-6 and etoposide or cytarabine for
48 hours. Apoptosis was determined by flow cytometry. The results shown are representative of 3 independent experiments. C, Apoptosis-inducing
capacity of Tenovin-6 plus etoposide or cytarabine was examined by Western blotting for cleaved PARP in ALL cells treated with drug combinations
for 48 hours.
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effect method of Chou and Talalay [20]. Both the combin-
ation of Tenovin-6 and etoposide and the combination of
Tenovin-6 and cytarabine synergistically (i.e., combination
index < 1) inhibited the viability of ALL cells (Figure 5A).
This enhanced effect was further supported by an increase
in the proportion of apoptotic cells as evaluated with flow
cytometry after Annexin V-FITC/propidium iodide staining
and with Western blotting for specific cleavage of PARP, an
indicator of apoptosis (Figure 5B and C). Taken together,
these data indicated that treatment withTenovin-6 sensitizes
ALL cells to conventional chemotherapeutic agents.
Tenovin-6 inhibits the Wnt/β-catenin pathway in ALL cells
Canonical Wnt signaling is activated via ligation of Wnt
proteins to their respective cell surface receptors Frizzled
and LRP6 on HSCs, leading to activation and nuclear
translocation of β-catenin, complex formation with TCF,
and transcription of target genes. β-catenin is important
in the regulation of self-renewal of cancer stem cells [25].
Previous studies showed that SIRT1 is involved in regula-
tion of the Wnt pathway by forming a complex with
β-catenin protein and Dishevelled (Dvl) [26]. In addition,
p53 was shown to be capable of down-regulating β-catenin
level [27]. We therefore asked whether sirtuin inhibition by
Tenovin-6 inhibits the Wnt/β-catenin pathway in ALL
cells. As anticipated, Tenovin-6 dramatically decreased
the total protein level of β-catenin in a time- and
concentration-dependent manner (Figure 6A). Because
cyclin D1, c-Myc, and LEF1 are known Wnt target
genes, we also ascertained the protein levels of these
genes [28]. We found that Tenovin-6 treatment sup-
pressed the expression of cyclin D1 and c-Myc (Figure 6A).
Decreased expression of the downstream target genes
were further proved by real-time qRT-PCR analysis in
Tenovin-6-treated ALL cells (Figure 6B).
Because inhibition of SIRT1 could lead to reduction in
Dvl proteins [26], we determined whether Tenovin-6
inhibited the protein level of Dvl3 in ALL cells. Western
blotting analysis in whole cell lysates revealed that the
protein levels of Dvl3 were strikingly lower in both REH
and NALM-6 cells treated with Tenovin-6 than in un-
treated control cells (Figure 6C, lower 2 lanes).
We also determined the effect of Tenovin-6 on the
β-catenin level in the nuclear fraction, which reflectsactive β-catenin. Tenovin-6 treatment led to decreased
β-catenin levels in the nuclear fractions of ALL cells
(Figure 6C, upper 2 lanes). Nuclear translocation of
β-catenin is required for its functions (i.e., to activate
TCF/LEF). Electrophoretic mobility shift assay (EMSA)
with TCF/LEF probes revealed a concentration-dependent
decrease in nuclear β-catenin in Tenovin-6-treated ALL
cells (Figure 6D). Together, these results indicated that
Tenovin-6 inhibits Wnt/β-catenin signaling in ALL cells.
Tenovin-6 eliminates stem/progenitor cells in ALL cells
CD133+/CD19- subfractions from pediatric B-ALL cells
are believed to be stem/progenitor cells capable of self-
renewing and differentiating into heterogeneous leukemia
cells [29]. We next examined the effect of Tenovin-6 on
these phenotypically defined stem/progenitor cells from
pediatric ALL specimens. With the MACS MicroBead kit,
we separated the CD133+ cells from bone marrow mono-
nuclear cells from patients with B-ALL. The purity of the
separated cells was confirmed by flow cytometry after
incubation with CD133-APC antibody. The sorted CD133+
cells were untreated or treated with 5 μM Tenovin-6 for
48 hours and then subjected to flow cytometry after staining
with Annexin V-FITC and CD19-phycoerythrin. Tenovin-6
significantly increased the Annexin V + CD133 + CD19−
subpopulation from primary ALL cells (Figure 6E),
suggesting that Tenovin-6 treatment eliminates ALL
stem/progenitor cells.
Discussion
Novel targeted therapy for ALL is desperately needed. In
the present study, we showed that Tenovin-6, an inhibi-
tor of the class III histone deacetylase sirtuin, was effect-
ive as a single agent and in combination with frontline
chemotherapeutics against ALL cells. Tenovin-6 treat-
ment activated p53 and induced cell growth inhibition
and apoptosis in ALL cell lines and primary ALL cells.
Furthermore, we found that Tenovin-6-induced inhib-
ition of SIRT1/2 activity decreased Wnt/β-catenin sig-
naling and eliminated ALL stem/progenitor cells.
SIRT1 deacetylates histone and nonhistone proteins
that are involved in many cellular functions. Although
the role of SIRT1 in tumorigenesis remains controversial
[30-33], SIRT1 expression was shown to be significantly
elevated in a number of human cancers, including acute
Figure 6 (See legend on next page.)
Jin et al. BMC Cancer  (2015) 15:226 Page 12 of 15
(See figure on previous page.)
Figure 6 Tenovin-6 suppresses Wnt/β-catenin signaling in ALL cells and eliminates ALL stem/progenitor cells. A, REH and NALM-6 cells
were treated with various concentrations of Tenovin-6 for 24 and 48 hours. Expression of β-catenin, c-myc, and cyclin D1 was detected by
Western blotting with the indicated antibodies. B, REH and NALM-6 cells were treated with increasing concentrations of Tenovin-6 for
48 hours, and then qRT-PCR analysis of β-catenin target genes (c-Myc, cyclin D1, and LEF1) was performed using intron-spanning primers. C, REH and
NALM-6 cells were treated with various concentration of Tenovin-6 for 48 hours. Western blotting for Dvl3 in total cell lysate and β-catenin in nuclear
extract was performed. PCNA was used as a nuclear protein reference. D, EMSA. Nuclear fractions from REH and NALM-6 cells treated with increasing
concentration of Tenovin-6 for 48 hours were incubated with wild-type biotin-labeled TCF probe. Cold competition assay was done using
100-fold unlabeled wild-type probe. E, CD133 MicroBeads separating system was applied to bone marrow mononuclear cells of 3 patients
with ALL. The sorted CD133+ cells were then untreated or treated with 5 μM Tenovin-6 for 48 hours, and apoptosis was evaluated by flow
cytometry after cells were stained with Annexin V-FITC and CD19-phycoerythrin.
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cancer [36], skin squamous cell carcinoma [37], che-
moresistant leukemia [38], and CD133-positive glioblast-
oma stem cells [39]. In accord with these findings, our
results showed that the expression of SIRT1 was ele-
vated in primary ALL cells compared with control. Of
note, SIRT1 has been demonstrated to promote the de-
velopment of chronic myelogenous leukemia [18,19].
A number of nonspecific and specific inhibitors of
SIRT1 have been discovered, including nicotinamide, sir-
tinol, splitomicin, HR73, cambinol [32], the tenovins
[24], and the indole derivative EX527. Two of these in-
hibitors, cambinol [32] and tenovin [24], were tested in
animal models of cancer and showed great antitumor ef-
fect against Burkitt lymphoma and melanoma, respect-
ively. In an in vitro peptide deacetylase activity assay,
Tenovin-6 was shown to inhibit the activity of SIRT1
and SIRT2 with IC50 values of 21 μM and 10 μM, respect-
ively. Our results in the current study demonstrated that
treatment of ALL cells with Tenovin-6 at even 1 μM led
to hyperacetylation and activation of p53 within approxi-
mately 2 to 6 hours.
Results of the present study indicated that Tenovin-6
treatment inhibits growth and induces apoptosis both in
ALL cell lines and in primary ALL cells at micromolar
concentrations, however, many ALL cells were sensitive
to the agents, while several cells were resistant (Figure 3C).
We assume that the sensitivity correlates with the p53
mutation status or with the SIRT1/2 expressions, this
remains to be further investigated. Of importance,
Tenovin-6 is synergistic with the conventional che-
motherapeutic agents etoposide and cytarabine and
also active against primary cells from patients with re-
lapsed ALL. Tenovin-6 disturbed the cell cycle distri-
bution in ALL cells by restricting the cells in G1
phase. The inhibitory effect of Tenovin-6 on cell growth
and survival may be explained by the activation of p53
and elevation of p21 after Tenovin-6 treatment.
Cancer stem cells are resistant to chemotherapy and
believed to be the source of relapse of tumor. Using
phenotypically defined stem/progenitor cells and func-
tional assay, we first showed that Tenovin-6-induced in-
hibition of SIRT1/2 eliminated ALL stem/progenitor cells.The CD133 + CD19- fraction in ALL cells represents
the stem/progenitor cells of ALL. We then found that
Tenovin-6 induced marked apoptosis in ALL stem/
progenitor cells. Furthermore, Tenovin-6 significantly
inhibited the colony-forming capacity of ALL cells
(Figure 3D & E).
Tenovin-6-mediated decrease in β-catenin, a key regula-
tor of self-renewal of cancer stem cells may be involved in
the elimination of ALL stem/progenitor cells. Our data
demonstrated that Tenovin-6 remarkably lowered the levels
of total and active β-catenin and blocked the downstream
signaling. The underlying mechanism may be associated
with Tenovin-6-induced Dvl inhibition and p53 activation.
SIRT1 can form a complex with β-catenin and Dvl [26].
Tenovin-6-induced Dvl inhibition is postulated to reduce
the stability of the complex. p53 can negatively regulate
β-catenin level [40]. Activation of p53 by Tenovin-6
may thus reasonably explain the decrease in β-catenin.
In summary, we found that the novel sirtuin inhibitor
Tenovin-6 is effective in killing pre-B ALL cells and
eradicating ALL stem/progenitor cells (CD133 + CD19-).
Tenovin-6 may represent an important therapeutic agent
against pre-B ALL alone or in combination with stand-
ard chemotherapeutics and is therefore worthy of further
clinical investigation in ALL.
Conclusions
In the present study, we initially found that the level of
SIRT1, a class III histone deacetylase, was higher in pri-
mary ALL cells from patients than in peripheral blood
mononuclear cells from healthy individuals. we found
that the novel sirtuin inhibitor Tenovin-6 is effective in
killing pre-B ALL cells and eradicating ALL stem/pro-
genitor cells (CD133 + CD19-). Tenovin-6 may represent
an important therapeutic agent against pre-B ALL alone
or in combination with standard chemotherapeutics and
is therefore worthy of further clinical investigation in ALL.
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